Cargando…

SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES

INTRODUCTION: Brain metastases (BMs) occur in 10-30% of adult patients with cancer. The therapeutic approach for BMs depends on several factors including lesion number, location and size, primary cancer type, and the patient’s overall health. ASCO-SNO-ASTRO guidelines conditionally recommend stereot...

Descripción completa

Detalles Bibliográficos
Autores principales: Cialdella, Fia, van Grinsven, Eva, van der Boog, Arthur, Nagtegaal, Steven, Smid, Ernst, Claes, An, Kleynen, Karin, Seravalli, Enrica, Philippens, Marielle, van Zandvoort, Martine, Verhoeff, Joost
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402386/
http://dx.doi.org/10.1093/noajnl/vdad070.106
_version_ 1785084865159364608
author Cialdella, Fia
van Grinsven, Eva
van der Boog, Arthur
Nagtegaal, Steven
Smid, Ernst
Claes, An
Kleynen, Karin
Seravalli, Enrica
Philippens, Marielle
van Zandvoort, Martine
Verhoeff, Joost
author_facet Cialdella, Fia
van Grinsven, Eva
van der Boog, Arthur
Nagtegaal, Steven
Smid, Ernst
Claes, An
Kleynen, Karin
Seravalli, Enrica
Philippens, Marielle
van Zandvoort, Martine
Verhoeff, Joost
author_sort Cialdella, Fia
collection PubMed
description INTRODUCTION: Brain metastases (BMs) occur in 10-30% of adult patients with cancer. The therapeutic approach for BMs depends on several factors including lesion number, location and size, primary cancer type, and the patient’s overall health. ASCO-SNO-ASTRO guidelines conditionally recommend stereotactic radiosurgery (SRS) for 1-10 BMs. The aim of this study was to investigate the outcomes of radiotherapy in patients with 5 or more BMs using SRS. METHODS: We implemented the prospective Cohort for patient-reported Outcomes, Imaging and trial inclusion in Metastatic BRAin disease (COIMBRA) to examine all patients with BM(s) who underwent radiotherapy. In this sub-study we investigated overall survival (OS) and health related quality of life (HRQoL) for 47 patients with 5 to 20 BMs. We evaluated patients’ HRQoL using the EQ5D-VAS, at baseline and at 3 monthly intervals after radiotherapy. RESULTS: Median OS was 21.3 months for patients with 5-10 BMs (n=38) and 12.5 months for patients with >10 BMs (n=9). Questionnaires at both baseline and 6 months after radiotherapy showed stability or improvement on the EQ5D-VAS after radiotherapy in 58.1%. Additionally, independence in self-care was not limited before or after SRS. Also, the proportion of patients (66.7%) reporting no limitation on their ability to do daily activities remained stable after radiotherapy. Fewer patients reported pain or other discomfort after SRS compared to before (25% vs 40%). CONCLUSION: Our findings suggest that radiotherapy may improve QoL in patients with 5-20 BMs. Furthermore, compared to the literature, we observed a prolonged OS in this prospective cohort, suggesting that SRS should be considered as the treatment option for these patients. These results highlight the need for further investigation of the role of SRS instead of Whole Brain Radiotherapy (WBRT) in the management of patients with multiple BMs.
format Online
Article
Text
id pubmed-10402386
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104023862023-08-05 SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES Cialdella, Fia van Grinsven, Eva van der Boog, Arthur Nagtegaal, Steven Smid, Ernst Claes, An Kleynen, Karin Seravalli, Enrica Philippens, Marielle van Zandvoort, Martine Verhoeff, Joost Neurooncol Adv Final Category: Supportive Care/Health Outcomes INTRODUCTION: Brain metastases (BMs) occur in 10-30% of adult patients with cancer. The therapeutic approach for BMs depends on several factors including lesion number, location and size, primary cancer type, and the patient’s overall health. ASCO-SNO-ASTRO guidelines conditionally recommend stereotactic radiosurgery (SRS) for 1-10 BMs. The aim of this study was to investigate the outcomes of radiotherapy in patients with 5 or more BMs using SRS. METHODS: We implemented the prospective Cohort for patient-reported Outcomes, Imaging and trial inclusion in Metastatic BRAin disease (COIMBRA) to examine all patients with BM(s) who underwent radiotherapy. In this sub-study we investigated overall survival (OS) and health related quality of life (HRQoL) for 47 patients with 5 to 20 BMs. We evaluated patients’ HRQoL using the EQ5D-VAS, at baseline and at 3 monthly intervals after radiotherapy. RESULTS: Median OS was 21.3 months for patients with 5-10 BMs (n=38) and 12.5 months for patients with >10 BMs (n=9). Questionnaires at both baseline and 6 months after radiotherapy showed stability or improvement on the EQ5D-VAS after radiotherapy in 58.1%. Additionally, independence in self-care was not limited before or after SRS. Also, the proportion of patients (66.7%) reporting no limitation on their ability to do daily activities remained stable after radiotherapy. Fewer patients reported pain or other discomfort after SRS compared to before (25% vs 40%). CONCLUSION: Our findings suggest that radiotherapy may improve QoL in patients with 5-20 BMs. Furthermore, compared to the literature, we observed a prolonged OS in this prospective cohort, suggesting that SRS should be considered as the treatment option for these patients. These results highlight the need for further investigation of the role of SRS instead of Whole Brain Radiotherapy (WBRT) in the management of patients with multiple BMs. Oxford University Press 2023-08-04 /pmc/articles/PMC10402386/ http://dx.doi.org/10.1093/noajnl/vdad070.106 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Supportive Care/Health Outcomes
Cialdella, Fia
van Grinsven, Eva
van der Boog, Arthur
Nagtegaal, Steven
Smid, Ernst
Claes, An
Kleynen, Karin
Seravalli, Enrica
Philippens, Marielle
van Zandvoort, Martine
Verhoeff, Joost
SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title_full SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title_fullStr SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title_full_unstemmed SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title_short SPCR-07 REDEFINING BOUNDARIES: STEREOTACTIC RADIOSURGERY FOR ENHANCED QUALITY OF LIFE AND SURVIVAL IN PATIENTS WITH 5-20 BRAIN METASTASES
title_sort spcr-07 redefining boundaries: stereotactic radiosurgery for enhanced quality of life and survival in patients with 5-20 brain metastases
topic Final Category: Supportive Care/Health Outcomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402386/
http://dx.doi.org/10.1093/noajnl/vdad070.106
work_keys_str_mv AT cialdellafia spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT vangrinsveneva spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT vanderboogarthur spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT nagtegaalsteven spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT smidernst spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT claesan spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT kleynenkarin spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT seravallienrica spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT philippensmarielle spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT vanzandvoortmartine spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases
AT verhoeffjoost spcr07redefiningboundariesstereotacticradiosurgeryforenhancedqualityoflifeandsurvivalinpatientswith520brainmetastases